<DOC>
	<DOCNO>NCT02920697</DOCNO>
	<brief_summary>The purpose study determine safety profile tolerability S 55746 patient CLL , B-Cell NHL MM , term Dose-Limiting Toxicities ( DLTs ) , Maximum Tolerated Dose ( MTD ) determine Recommended Phase 2 Dose ( RP2D ) safety profile ( DLT , MTD ) , PK profile , PD profile preliminary efficacy .</brief_summary>
	<brief_title>Dose-escalation Study Oral Administration S 55746 Patients With Chronic Lymphocytic Leukaemia B-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Women men age &gt; /=18 year Patients measurable histologically confirm Follicular Lymphoma ( FL ) , Mantle Cell Lymphoma ( MCL ) , Diffuse Large BCell Lymphoma ( DLBCL ) , Small Lymphocytic Lymphoma ( SLL ) Marginal Zone Lymphoma ( MZL ) ( Arm A ) , patient evaluable immunophenotypically confirm CLL ( Arm B ) , patient measurable Multiple Myeloma ( 11 ; 14 ) ( arm A expansion part ) accord International Myeloma Working Group ( IMWG ) criterion Relapsed refractory disease standard treatment , require treatment opinion investigator Estimated life expectancy &gt; 12 week World Health Organization ( WHO ) performance status 02 Adequate bone marrow , renal hepatic function , normal coagulation profile No evidence treatment another malignancy within 2 year prior study entry . Curatively treated nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia allow Additional inclusion criterion food interaction cohort : Bcell NHL patient low risk tumour lysis syndrome ( TLS ) Recent/concomitant treatment alter gastric pH Previous treatment BH3 mimetic Previous therapy study disease within 3 week first intake Radioimmunotherapy , radiotherapy within 8 week first intake Major surgery within 3 week first day study drug dose Corticosteroids &gt; = 20 mg prednisone equivalent per day within 7 day first intake Anticoagulant oral drug , aspirin &gt; 325 mg/day Positive direct antiglobulin test ( Coombs test ) haptoglobin normal value Prior allogenic stem cell transplant Autologous stem cell transplant within 3 month first intake NHL patient diagnose PostTransplant Lymphoproliferative Disease , Burkitt 's lymphoma , Burkittlike lymphoma , lymphoblastic lymphoma/leukaemia Human immunodeficiency virus ( HIV ) Known acute chronic hepatitis B hepatitis C Impaired cardiac function Medications know prolong correct QT ( QTc ) interval History or/ clinically suspicious cancer related Central Nervous System disease Solitary extramedullary plasmacytoma Laboratory Signs TLS Strong moderate CYP3A4 inhibitors/inducers ( treatment , food drink product ) Treatment highly metabolize CYP3A4 CYP2D6 and/or substrate narrow therapeutic index , multienzyme and/or OATP substrates herbal product . Known hypersensitivity rasburicase Glucose6phosphate dehydrogenase ( G6PD ) deficiency cellular metabolic disorder know cause haemolytic anaemia Patients receive proton pump inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>